Fresenius Launches Posaconazole Injection for Treatment of Fungal Infections
DUBLIN, June 29, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping posaconazole injection (18 mg/mL), the first generic version of Merck's Noxafil® in the U.S., following final approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application.
Mylan's Generic (Posaconazole) Receives Approval in the U.S.
Welding's Generic (Posaconazole) Receives Approval in the U.S.
DUBLIN, April 3, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S.
Enforcement Report - Week of February 15, 2023
Amneal's Generic Posaconazole Receives Approval in the U.S.
Amneal`s Generic Posaconazole Receives Approval in the U.S.
Hetero's Generic Posaconazole Receives Approval in the U.S.
Current study intended to prepare and evaluate phospholipid-based, mixed micelles (MMs) to improve the ocular delivery of posaconazole (POS), a broad-spectrum antifungal drug. For this, MMs based on egg phosphatidylcholine (EPC), as the main component, in combination with various bile salts (sodium cholate (NaC), sodium deoxycholate (NaDC), sodium taurocholate (NaTC)) or non-ionic surfactants (Pluronic® F-127, Pluronic® F-68, Tween 80, Labrasol® ALF, and d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS)) were prepared. Particle size, polydispersity index, zeta potential and entrapment efficiency were evaluated to optimize the composition and preparation method of the MMs.